Georgios Papathanakos

Dr. Georgios Papathanakos

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
GPGeorgios Papathanakos
Georgios Papathanakos
IAIoannis Andrianopoulos
Ioannis Andrianopoulos
APAthanasios Papathanasiou
Athanasios Papathanasiou
EPEfthalia Priavali
Efthalia Priavali
Despoina KoulentiDespoina Koulenti
Despoina Koulenti
VKVasilios Koulouras
Vasilios Koulouras
The prevalence of acinetobacter baumannii (AB) as a cause of hospital infections has been rising. Unfortunately, emerging colistin resistance limits therapeutic options and affects the outcome. The aim of the study was to confirm our clinically-driven hypothesis that intensive care unit (ICU) patients with AB resistant-to-colistin (ABCoR) bloodstream infection (BSI) develop fulminant septic shock and die. We conducted a 28-month retrospective observational study including all patients developing AB infection on ICU admission or during ICU stay. From 622 screened patients, 31 patients with BSI sepsis were identified. Thirteen (41.9%) patients had ABCoR BSI and 18/31 (58.1%) had colistin-susceptible (ABCoS) BSI. All ABCoR BSI patients died; of them, 69% (9/13) presented with fulminant septic shock and died within the first 3 days from its onset. ABCoR BSI patients compared to ABCoS BSI patients had higher mortality (100% vs. 50%, respectively (p = 0.001)), died sooner (p = 0.006), had lower pH (p = 0.004) and higher lactate on ICU admission (p = 0.0001), and had higher APACHE II (p = 0.01) and Charlson Comorbidity Index scores (p = 0.044). In conclusion, we documented that critically ill patients with ABCoR BSI exhibit fulminant septic shock with excessive mortality. Our results highlight the emerging clinical problem of AB colistin resistance among ICU patients.

27 August 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
GPGeorgios Papathanakos
Georgios Papathanakos
IAIoannis Andrianopoulos
Ioannis Andrianopoulos
MXMenelaos Xenikakis
Menelaos Xenikakis
APAthanasios Papathanasiou
Athanasios Papathanasiou
Despoina KoulentiDespoina Koulenti
Despoina Koulenti
VKVasilios Koulouras
Vasilios Koulouras
Sepsis, defined as the life-threatening dysregulated host response to an infection leading to organ dysfunction, is considered as one of the leading causes of mortality worldwide, especially in intensive care units (ICU). Moreover, sepsis remains an enigmatic clinical syndrome, with complex pathophysiology incompletely understood and a great heterogeneity both in terms of clinical expression, patient response to currently available therapeutic interventions and outcomes. This heterogeneity proves to be a major obstacle in our quest to deliver improved treatment in septic critical care patients; thus, identification of clinical phenotypes is absolutely necessary. Although this might be seen as an extremely difficult task, nowadays, artificial intelligence and machine learning techniques can be recruited to quantify similarities between individuals within sepsis population and differentiate them into distinct phenotypes regarding not only temperature, hemodynamics or type of organ dysfunction, but also fluid status/responsiveness, trajectories in ICU and outcome. Hopefully, we will eventually manage to determine both the subgroup of septic patients that will benefit from a therapeutic intervention and the correct timing of applying the intervention during the disease process.

4 March 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
ΒΠΒΑΡΒΑΡΑ ΠΑΚΟΥ
ΒΑΡΒΑΡΑ ΠΑΚΟΥ
DTDimitrios N. Tsartsalis
Dimitrios N. Tsartsalis
GPGeorgios Papathanakos
Georgios Papathanakos
Elena DragiotiElena Dragioti
Elena Dragioti
Mary GouvaMary Gouva
Mary Gouva
VKVasilios Koulouras
Vasilios Koulouras
This study explored the associations between personality dimensions, burnout, and psychopathology in healthcare professionals in intensive care units (ICUs). This study further aimed to discern the differences in these relationships when considering the variables of critical care experience (less than 5 years, 5–10 years, and more than 10 years), profession (nurses versus intensivists), and the urban size of the city where the ICU is located (metropolitan cities versus smaller urban cities). This cross-sectional investigation’s outcomes are based on data from 503 ICU personnel, including 155 intensivists and 348 nurses, in 31 ICU departments in Greece. Participants underwent a comprehensive assessment involving a sociodemographic questionnaire, the Eysenck Personality Questionnaire (EPQ), the Maslach Burnout Inventory (MBI), and the Symptom Checklist-90 (SCL-90). To analyze the interplay among critical care experience, burnout status, and psychopathology, a moderation analysis was conducted with personality dimensions (i.e., psychoticism, extraversion, and neuroticism) serving as the mediator variable. Profession and the urban size of the ICU location were considered as moderators influencing these relationships. Male healthcare professionals showed higher psychoticism levels than females, aligning with prior research. Experienced nurses reported lower personal achievement, hinting at potential motivation challenges for professional growth. Psychoticism predicted high depersonalization and low personal achievement. Neuroticism and psychoticism negatively impacted ICU personnel’s mental well-being, reflected in elevated psychopathology scores and burnout status. Psychoticism appears to be the primary factor influencing burnout among the three personality dimensions, particularly affecting intensivists. In contrast, nurses are more influenced by their critical care experience on their mental health status.

29 July 2024 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
JPJosé-Artur Paiva
José-Artur Paiva
JRJordi Rello
Jordi Rello
CEChristian Eckmann
Christian Eckmann
MAMassimo Antonelli
Massimo Antonelli
KAKostoula Arvaniti
Kostoula Arvaniti
SBStijn Blot
Stijn Blot

29 June 2020 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
GPGeorgios Papathanakos
Georgios Papathanakos
IAIoannis Andrianopoulos
Ioannis Andrianopoulos
APAthanasios Papathanasiou
Athanasios Papathanasiou
DKDespoina Koulenti
Despoina Koulenti
KGKonstantina Gartzonika
Konstantina Gartzonika
VKVasilios Koulouras
Vasilios Koulouras

5 July 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
MAMaria Panagiota Almyroudi
Maria Panagiota Almyroudi
ACAina Chang
Aina Chang
IAIoannis Andrianopoulos
Ioannis Andrianopoulos
GPGeorgios Papathanakos
Georgios Papathanakos
RMReena Mehta
Reena Mehta
DKDespoina Koulenti
Despoina Koulenti
Nosocomial pneumonia, including hospital-acquired pneumonia and ventilator-associated pneumonia, is the leading cause of death related to hospital-acquired infections among critically ill patients. A growing proportion of these cases are attributed to multi-drug-resistant (MDR-) Gram-negative bacteria (GNB). MDR-GNB pneumonia often leads to delayed appropriate treatment, prolonged hospital stays, and increased morbidity and mortality. This issue is compounded by the increased toxicity profiles of the conventional antibiotics required to treat MDR-GNB infections. In recent years, several novel antibiotics have been licensed for the treatment of GNB nosocomial pneumonia. These novel antibiotics are promising therapeutic options for treatment of nosocomial pneumonia by MDR pathogens with certain mechanisms of resistance. Still, antibiotic resistance remains an evolving global crisis, and resistance to novel antibiotics has started emerging, making their judicious use crucial to prolong their shelf-life. This article presents an up-to-date review of these novel antibiotics and their current role in the antimicrobial armamentarium. We critically present data for the pharmacokinetics/pharmacodynamics, the in vitro spectrum of antimicrobial activity and resistance, and in vivo data for their clinical and microbiological efficacy in trials. Where possible, available data are summarized specifically in patients with nosocomial pneumonia, as this cohort may exhibit ‘critical illness’ physiology that affects drug efficacy.